Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRI-611 in Advanced ALK-Positive NSCLC
NCT07491497Phase 2Recruiting
- Sponsor
- TRIANA Biomedicines
- Start
- Mar 2026
- Primary completion
- May 2029
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
A Phase 2 trial of TRI-611 in non-small cell lung cancer (NSCLC), sponsored by TRIANA Biomedicines. Started Mar 2026; status: recruiting.
02
Drugs
TRI-611
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07491497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491497.